Ezequiel A. Camerini, David C. Camerini, and Tomás M. Casalins, members of the firm's Latin American practice group headed by Mr. Camerini, represented the shareholders of Laboratorios Phoenix S.A.C.yF, a leading Argentine pharmaceutical company, in the all cash sale of Phoenix to GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare businesses, for approximately US$253 Million. Rafael A. Ginebra and V. David Rivkin, also members of the firm assisted with a licensing arrangement which was entered into as part of the sale transaction. Phoenix's portfolio includes brands in the prescription and over-the-counter (OTC) markets for therapeutic areas such as cardiovascular, gastroenterology, metabolic, respiratory, anti-inflammatory, psychiatry, neurology, ophthalmology and urology. Phoenix has over 40 drugs in its prescription-drugs portfolio, and its OTC portfolio includes most antiseptics and dietary supplements.